Compare Citius Pharmaceuticals Inc (CTXR) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Petróleo Brasileiro SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Petróleo Brasileiro SA trades at $17.97 (market cap $108.05B). The key difference: Petróleo Brasileiro SA is far larger — about 7380.5× Citius Pharmaceuticals Inc's market cap, and Petróleo Brasileiro SA pays a 9.84% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PBR | |
|---|---|---|
Market Cap | $14.64M | $108.05B |
Sector | Health | Technology |
52-Week High | $1.82 | $22.03 |
52-Week Low | $0.53 | $11.54 |
Enterprise Value | $10.86M | $170.59B |
Dividend Yield | — | 9.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
PBR trades at $17.88, up 3.23% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamentals with a P/E of 5.71, net income margin of 21.47%, and consistent dividend payments. Recent developments include strategic acquisitions in Africa and renewable energy investments, supporting growth prospects amid positive analyst sentiment.
Outlook remains favorable with a consensus price target of $23.90, representing 33.6% upside potential. Key risks include oil price volatility and execution of new projects. The combination of low valuation, robust cash flow, and strategic expansion provides a compelling case for long-term investors, though market fluctuations warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
